LETTERS
These letters are selected from rapid responses posted on bmj.com. Selection is usually made 12 days after print publication of the article to which they respond.
TRAVEL WEBSITES

Travel websites should highlight malaria risks
We are concerned about three recent cases of imported malaria in travellers returning from the Gambia. All three were UK nationals who had booked holidays to the Gambia using the same travel website (two had made late bookings). They had failed to take adequate medical advice before travelling so did not take adequate malaria chemoprophylaxis. Within a fortnight of returning to the UK they all presented to hospital with severe Plasmodium falciparum malaria.
Imported cases of malaria are relatively common in the UK, mostly from west Africa (813 of 1495 cases in 2009), with a considerable proportion occurring in holidaymakers (57 in 2009).
1 The Gambia is a popular "winter sun" destination for UK travellers. Malaria is highly endemic there and is a risk to travellers throughout the year. This risk can be reduced through appropriate chemoprophylaxis and bite avoidance interventions. 2 The increasing use of websites to make late holiday bookings can make it more difficult to organise medical advice and malaria chemoprophylaxis. 3 In addition, many travel websites and holiday brochures, including the website used by our patients, make no specific reference to the risk of contracting malaria. 4 Travel websites need to include explicit messages about taking medical advice and effective chemoprophylaxis before travelling to malaria endemic areas. Advice on allowing sufficient time to organise this might reduce the particular risk to people making late bookings.
THROMBOLYSIS IN ELDERLY PEOPLE
Observational data insufficient to change treatment
The paper by Mishra and colleagues suggests that age should not be a barrier to stroke thrombolysis, 1 but caution is advised when using observational data to change clinical practice.
SITS is a voluntary register, so does not include all patients who receive recombinant tissue plasminogen activator (rt-PA), and those who have adverse events (such as haemorrhage and death) may be omitted. VISTA is a trials registry, so includes all patients without selective loss. Therefore a selection bias could produce the apparent difference between outcomes observed in the SITS and VISTA data (attributed to rt-PA).
A further weakness is the lack of data on time to treatment. SITS is a registry of rt-PA use generally within licence and therefore largely refers to patients treated within three hours, at most four and a half hours, after stroke. The neuroprotective trials in VISTA had time windows of six hours. Were the cases matched by treatment delay? These two biases could explain the beneficial absolute decrease in deaths of 3.5% at three months seen in the alteplase treated patients in their analyses, which differs from the systematic review data (showing no mortality benefit).
2 The increased risk of symptomatic intracranial haemorrhage in those over 80 (11%) v those of 80 and under (8.3%) (odds ratio1.4, 95% confidence interval 1.2 to1.6; P<0.001), in their study is worrying and consistent with other data suggesting that treatment of those over 80 may result in poorer outcomes.
3
Thrombolysis is a promising treatment for those over 80 years, but until the results of the third international stroke trial (www.ist3.com) are reported (expected in the first half of 2012), doctors should randomly allocate appropriate patients to the ongoing trials (IST-3, TESPI) to ensure that evidence of effectiveness is robust for the 21st century. Authors' reply Our paper details the measures taken to preclude bias and acknowledges potential overestimation of effects, 1 but residual caution over design issues should be assuaged by the simple expedient of comparing the treatment effect in the elderly against that in young people.
2 These controlled data now encompass 2612 very elderly patients who received alteplase plus a similar number of controls. Intriguing as further randomised data will be, subgroup analysis of an open label trial spanning 13 years will require close scrutiny since these will be selected patients, treated with unblinded assessment of early responses by centres that had doubts about their capability to deliver alteplase safely, or about treatment efficacy even within three or four and a half hours, or about other patient characteristics that may increase risk or diminish benefit.
What do we know reliably about risk and benefit in elderly people? The risk of symptomatic Neither is serious bleeding more common in patients over 90. 4 For benefit, three controlled comparisons of patients treated with alteplase are available, one randomised, and all indicate comparable advantage from treatment (figure). Each comparison matches the proved effects in younger patients.
2 3 5 With this evidence, we would find it challenging to defend randomisation to placebo of an otherwise suitable candidate for treatment, simply on grounds of age. Stroke is a disease of elderly people: let us not deprive them of proved treatment. 3 Sales representatives cannot be depended on to provide fair and balanced comparative information on the drugs they promote, and they will never provide that kind of information. Whether they give fewer or more gifts to doctors, they are duty bound to provide, and have a vested interest (higher bonus) in providing, non-comparative and commercially biased information.
And putting a positive spin on visits by French sales representatives is particularly galling with a scandal about benfluorex brewing in France. 4 Although not the primary culprits in this health scandal, they were implicated in promoting an anorectic agent under the guise of an antidiabetic, which was also associated with heart valve defects.
Regulated or unregulated, promotional information provided by sales representatives cannot be redeemed. The most effective strategy is for health professionals to refuse to see sales representatives and to rely on information sources that are independent of pharmaceutical companies. 
A FRENCH KING'S HEAD
Was it Henri IV's head?
Charlier and colleagues use an international multidisciplinary approach to identify the head of Henri IV.
1 However, the evidence for positive identification seems to be meagre, particularly from a medical point of view. Earrings were commonly worn by men in the 16th century. The maxillary bone lesion looks like a cyst, and the nasal naevus is not obvious. Moustache and beard hairs are commonly red and white in mummified bodies because of postmortem discoloration. Postmortem baldness is also common in mummies that have been handled a lot, as in this case. The digital superimposition does not correspond, especially at the nasal bones, and in any case is difficult to assess when one person has the mouth open and the other closed.
We also have an impressive and detailed report of the exhumations of the French kings in Saint Denis. The Benedictine Dom Germain Poirier and Alexandre Lenoir, responsible for historic monuments, witnessed the exhumations of October 1793 on behalf of the Committee of Monuments and accurately described the embalmed body of Henri IV (translated from the French):
On Saturday 12 October 1793 . . . his body was found to be well preserved, and the features of his face could be recognised perfectly . . . The skull of this corpse, considered a dry mummy, had been cut with a saw, and contained, in place of the brain, which had been removed totally, some tow imbued with an aromatic liquid, which gave out a smell that was so strong it was almost impossible to bear. 
Authors' reply
An osteo-archaeological identification must be based on both solid anthropological and historical data. Professor Fornaciari's doubts can be easily assuaged. 
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were confirmed by histology examination, avoiding any postmortem discoloration. The left upper maxillary bone scar lesion is localised bone production, and cysts are defined by osteolysis.
All facial superimposition and reconstitution were conducted and analysed according to the highest and most current standards of forensic anthropology.
The two texts by Alexandre Lenoir and Dom Poirier are much later than 1793. A direct analysis of the original texts conserved in the Archives Nationales (AE1 15) and the Archives of Paris (6A223, article 1391) shows that the description of the Henri IV opened skull is absent from the original manuscripts. The only original (and anonymous) source is a Historical Journal of the Coffin Extraction, which does not mention any opening in the skull. Many supplementary comments appear in subsequent versions of the texts by Dom Poirier and particularly Alexandre Lenoir (dating from 1801), transforming these primarily chronicle texts into true novel ones. To summarise, there are no serious data about a craniotomy having been performed or seen on the skull of Henri IV, unlike on the cadavers of many or possibly all other French kings.
Putting all these arguments together, nothing goes against the certainty of this osteoarchaeological identification. 
POINT OF CREDULITY
Professor McLachlan's fraud
McLachlan contacted the Jerusalem International Conference on Integrative Medicine asking to present his research findings. 1 He attached 11 impressive pages with his publication record, list of grants, and 70 scientific conferences he had lectured at. When a researcher of such status asks to present his work no one will refuse him, and he was offered 15 minutes for his presentation (flight and accommodation were not included).
McLachlan lied about research he never did and results he never got. But who would inquire into the credibility of someone who is professor, associate dean of medicine, and member of the school of medicine and health at Durham University, or doubt his written declaration that he conducted research?
No scientific committee in the world can be a perfect barrier to deceitful intentions. The main way to prevent deception is public exposure: anyone who claims research findings must publish them, and it is only a question of time until frauds will be uncovered. This is why McLachlan immediately broke off contact with the conference organisers once asked to confirm his arrival. Confirming his participation would have led to the preliminary publication of his abstract, and Jerusalem would probably have been the last conference in the world at which he could have lectured.
If I were an academic member of Durham University, I would be concerned that a researcher on my campus had written to a scientific committee about research he never did and results he never got, while signing with his campus's official title. On reflection, researchers around the world should be concerned by this phenomenon. Author's reply
Fried makes two points. 1 2 Firstly, that the abstract was accepted because of my credentials. But that was one of the points I was trying to make. My impression is that the world of alternative medicine is peculiarly susceptible to "arguments from authority," while rational science and medicine ought to focus solely on evidence.
The second point relates to "fraud." I would distinguish between fraud and "comic hoax," with the distinction lying in intent. A comic hoax always intends to reveal the truth in time, but fraud is meant to remain secret. Hoax tactics can be legitimate, even when the subject is not comic. The subject of the "lie," the idea that the buttocks map meaningfully to body organs is intrinsically risible to believers in rational medicine but not to believers in "alternative universe medicine." One commentator on the internet said: "Once you open your mind wide enough to find reflexology or homoeopathy 'not implausible,' then you have no defence against any nonsense that might wander in"-this is a fair summary of my position.
I thought seriously about the ethical aspects and had helpful discussions with colleagues, friends, and BMJ editorial staff. But part of my motivation was to create a "true anecdote" as an antidote to the simplified and false anecdotes used in alternative universe medicine, increasingly disguised in integrative medicine clothing, and I hope I did this.
I did think about attending the conference and would have revealed the hoax during the presentation. I don't think it would have been one of the last conferences that I could have participated in. My motives for not attending were as described, and not as imputed by Fried.
Those who hold positions that are not supported by rational means cannot readily be challenged by rationality. How then to address these positions? Surely a little humour is not misplaced? 
PHANTOM VIBRATION SYNDROME
Sixty eight per cent of us hallucinate
This survey showed that 68% of medical staff have sensory hallucinations. 1 I have experienced similar sensations when carrying a mobile phone with a vibrate function. Hallucinations are perceptions in the absence of a stimulus, and the authors are right to describe these sensations as such.
The authors suggest mechanisms that contribute to these hallucinations, and these can be synthesised through a cognitive formulation. An emotionally salient stimulus (a vibrating bleep indicating a potential medical emergency) experienced repeatedly in an aroused state (being on call) leads to a hypervigilant state where a similar perception is experienced in the absence of the stimulus. The authors suggest that this is more likely in junior medical staff, their inexperience possibly heightening their anxiety that a mistake made in responding to a medical emergency will have catastrophic consequences. The role of sleep deprivation, which lowers the threshold for hallucinations, is not reported but may contribute.
This formulation can also explain other common hallucinations. The lifelong companionship of couples experienced as repeated stimuli in all modalities leads to some bereaved people feeling, seeing, or hearing their loved ones soon after
2 This formulation can also help us understand the association between repeated abusive experiences in childhood and subsequent derogatory and intrusive voices in adults given a diagnosis of schizophrenia.
3 Acknowledging that 68% of doctors hallucinate and that "normal brain mechanisms" may be involved in the generation of hallucinations can reduce stigmatising attitudes towards severe mental illness and improve our attempts to help patients make sense of distressing and overwhelming experiences. 
CYCLING AND HEALTH
Pernicious use of surrogate markers
I am delighted that the BMJ recognises the importance of bicycles to international health. 1 However, the article is seriously flawed. First reports in a new field tend to be the most cited, regardless of subsequent and contrary evidence from better designed studies. Why has the BMJ allowed open access to this work? Now, rather than being confined to a small number of experts with the knowledge, skills, and training to evaluate the weaknesses of the claims made, the article is accessible to a general public that seriously lacks these attributes. Among those to whom the conclusions are available are spouses, partners, and family members of cyclists. Most of these people are greatly influenced by pseudoscientific claims appearing in print and electronic media and reluctant to acknowledge alternative viewpoints, no matter how well reasoned and scientifically sound.
It is ironic that Groves compares the uptake of new cycling technology to the uptake of new drugs when his major error is identical to one often encountered in drug trials-the measurement of surrogate outcomes. Who cares whether you save four minutes riding from Sheffield to Chesterfield? The more important questions are how does the rider feel about the journey on one type of bicycle versus the other; what impact does the bicycle have on the rider's self esteem and feeling of worth; how are the rider's interactions with colleagues, friends, and family affected by the type of machine that he or she rides? Until researchers shift their focus from the mechanistic to the psychosocial aspects of cycling, many of us will be condemned to riding junk.
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